What is the starting dose of insulin glargine (Lantus) for a newly diagnosed type 2 diabetes male weighing 66.4 kg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Starting Dose of Lantus for Newly Diagnosed Type 2 Diabetes

For a 66.4 kg male newly diagnosed with type 2 diabetes, start Lantus at either 10 units once daily OR 0.2 units/kg (approximately 13 units) once daily, administered subcutaneously at the same time each day.

Dosing Rationale

The FDA-approved Lantus label explicitly states that the recommended starting dose in patients with type 2 diabetes who are not currently treated with insulin is 10 units (or 0.2 units/kg) once daily 1. For this 66.4 kg patient, the weight-based calculation yields approximately 13 units (66.4 kg × 0.2 = 13.3 units).

Multiple clinical guidelines consistently support this dosing approach:

  • 2023 AACE guidelines recommend starting basal insulin at 0.1-0.2 units/kg/day for A1C <8%, or 0.2-0.3 units/kg/day for A1C >8% 2
  • 2021 ADA Standards of Care specify starting doses of 0.1-0.2 units/kg/day based on body weight and degree of hyperglycemia 3
  • 2017 ADA guidelines recommend either 10 units or 0.1-0.2 units/kg of basal insulin per day 4

Practical Implementation

Choose the starting dose based on baseline glycemic control:

  • If A1C <8% or fasting glucose 140-200 mg/dL: Start with 10 units (more conservative)
  • If A1C >8% or fasting glucose >200 mg/dL: Start with 13 units (0.2 units/kg)
  • If patient is elderly (≥70 years) or has impaired renal function (GFR <60): Start with 7 units (0.1 units/kg) 5

Titration schedule: Increase the dose by 2-4 units (or 10-15%) once or twice weekly until fasting blood glucose reaches target of 80-130 mg/dL 4, 2. The patient should adjust doses every 2-3 days based on self-monitored fasting glucose 2.

Critical Considerations

Concomitant therapy: Lantus should be used with metformin and possibly one additional non-insulin agent 4. Discontinue sulfonylureas when starting basal insulin to reduce hypoglycemia risk 2.

Common pitfall: Starting too conservatively delays glycemic control. Research demonstrates that a higher starting dose (0.3 units/kg) in overweight/obese patients achieves target glucose faster without increasing hypoglycemia risk 6. However, the FDA label and major guidelines support the more conservative 0.2 units/kg maximum for initial dosing.

Hypoglycemia management: If fasting glucose drops below 70 mg/dL, reduce the dose by 10-20%; if below 40 mg/dL, reduce by 20-40% 2.

Administration: Give once daily at the same time each day, subcutaneously in the abdomen, thigh, or deltoid. Rotate injection sites within the same region 1.

References

2
Guideline

american association of clinical endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2023

Related Questions

In a 53‑year‑old, 37‑kg woman with type 2 diabetes, insulin resistance, and a high‑carbohydrate diet, currently using insulin glargine (Lantus) 24 units daily, an insulin‑to‑carbohydrate ratio of 6 g per unit, and an insulin‑sensitivity factor of 25 mg/dL per unit, what should her insulin‑sensitivity factor, insulin‑to‑carbohydrate ratio, and basal insulin dose be adjusted to?
Should I increase the NPH insulin dose by 2 units at a time, waiting three days between each change, and prioritize the dose associated with the highest glucose reading?
For a 114 kg pregnant woman with diabetes, what is the appropriate starting dose of insulin glargine (Lantus) and how should the basal dose be titrated, including total daily insulin requirement, insulin‑to‑carbohydrate ratio, and correction factor?
For a 45-year-old Hispanic male weighing 98.4 kg with newly diagnosed type 2 diabetes and normal renal function, currently on 30 U insulin glargine (Lantus) and an insulin-to-carbohydrate ratio of 1 U per 5 g carbohydrate, with post‑meal insulin drip rates of 6, 4, 8, 6 U and overnight fasting drip rates of 2 U each hour, what should the insulin-to-carbohydrate ratio, basal insulin glargine dose, and insulin sensitivity factor be?
What is the appropriate insulin glargine (Lantus) dose for an 88‑year‑old man with type 2 diabetes, weight approximately 80 kg, and fasting glucose around 300 mg/dL?
Should regular intravenous fluids be given to a 52-year-old female with postural orthostatic tachycardia syndrome and a history of heart failure, myocardial infarction, and atrial fibrillation?
Does Bacteim (trimethoprim‑sulfamethoxazole) provide coverage for Pseudomonas aeruginosa, Proteus vulgaris, Klebsiella pneumoniae, and Citrobacter freundii?
What antihypertensive agents should be selected for a patient based on their comorbid conditions and contraindications?
What are the recommended oral antibiotics for an adult outpatient with a complicated urinary tract infection?
In a patient with autism spectrum disorder suspected of MTHFR deficiency, what genetic and laboratory testing is indicated and how should folate and vitamin B12 supplementation be initiated and monitored?
What is the appropriate management for neuroleptic malignant syndrome?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.